Stock Analysis on Net
Stock Analysis on Net

Allergan Inc. (NYSE:AGN.)

This company has been moved to the archive! The financial data has not been updated since February 19, 2015.

Balance Sheet: Assets 
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Allergan Inc., consolidated balance sheet: assets (quarterly data)

US$ in thousands

Microsoft Excel
Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013 Dec 31, 2012 Sep 30, 2012 Jun 30, 2012 Mar 31, 2012 Dec 31, 2011 Sep 30, 2011 Jun 30, 2011 Mar 31, 2011 Dec 31, 2010 Sep 30, 2010 Jun 30, 2010 Mar 31, 2010
Cash and equivalents 4,911,400 3,910,800 3,189,900 2,815,300 3,046,100 2,686,300 2,484,000 2,198,800 2,701,800 2,655,000 2,368,700 2,291,700 2,406,100 2,212,000 1,856,500 2,530,800 1,991,200 2,603,300 2,219,600 1,989,700
Short-term investments 55,000 274,600 525,600 802,000 603,000 524,600 184,800 50,000 260,600 279,900 304,800 349,800 179,900 66,500 299,800 249,700 749,100 499,300 — —
Trade receivables, net 914,500 967,400 1,055,000 990,400 883,300 908,200 917,200 887,900 764,200 872,600 867,900 855,700 730,600 710,900 744,200 671,600 647,300 586,900 601,300 558,700
Inventories 296,000 297,700 299,900 296,600 285,300 280,000 274,400 269,200 282,900 265,100 259,700 261,900 249,700 242,100 242,400 239,200 229,400 219,600 201,900 219,400
Other current assets 694,300 653,300 631,300 548,700 493,000 440,000 468,200 508,900 449,300 463,200 458,500 479,500 482,000 451,100 449,700 393,100 376,700 334,300 331,400 376,400
Assets of discontinued operations — — 1,200 5,700 9,000 93,300 153,600 154,700 — — — — — — — — — — — —
Current assets 6,871,200 6,103,800 5,702,900 5,458,700 5,319,700 4,932,400 4,482,200 4,069,500 4,458,800 4,535,800 4,259,600 4,238,600 4,048,300 3,682,600 3,592,600 4,084,400 3,993,700 4,243,400 3,354,200 3,144,200
Investments and other assets 271,900 236,900 238,700 226,100 213,200 191,600 194,400 193,200 192,100 191,700 240,400 247,600 247,100 266,900 261,600 258,500 261,400 288,600 273,400 268,400
Deferred tax assets 86,900 59,400 121,500 121,500 128,800 120,200 88,700 74,900 206,900 188,300 159,700 149,400 152,600 151,400 249,200 242,600 217,800 157,100 17,100 6,700
Property, plant and equipment, net 1,006,300 1,005,300 977,900 942,300 923,200 877,000 866,200 853,900 852,900 822,800 811,600 807,000 807,000 791,100 795,100 788,500 800,600 778,000 785,900 795,400
Goodwill 2,392,900 2,414,000 2,340,600 2,339,400 2,339,400 2,334,000 2,326,600 2,313,200 2,239,500 2,092,900 2,090,900 2,097,300 2,088,400 2,093,200 2,050,700 2,045,300 2,038,600 2,043,600 1,996,600 2,008,400
Intangibles, net 1,786,500 1,826,400 1,609,200 1,632,200 1,650,000 1,689,400 1,716,900 1,745,800 1,229,100 1,079,400 1,111,200 1,144,300 1,165,200 1,198,800 930,400 951,400 996,000 1,029,400 1,360,400 1,405,300
Non-current assets 5,544,500 5,542,000 5,287,900 5,261,500 5,254,600 5,212,200 5,192,800 5,181,000 4,720,500 4,375,100 4,413,800 4,445,600 4,460,300 4,501,400 4,287,000 4,286,300 4,314,400 4,296,700 4,433,400 4,484,200
Total assets 12,415,700 11,645,800 10,990,800 10,720,200 10,574,300 10,144,600 9,675,000 9,250,500 9,179,300 8,910,900 8,673,400 8,684,200 8,508,600 8,184,000 7,879,600 8,370,700 8,308,100 8,540,100 7,787,600 7,628,400

Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).

Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Allergan Inc. current assets increased from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014.
Property, plant and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Allergan Inc. property, plant and equipment, net increased from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014.
Non-current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Allergan Inc. non-current assets increased from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Allergan Inc. total assets increased from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Allergan Inc. cash and equivalents increased from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014.
Short-term investments Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. Allergan Inc. short-term investments decreased from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014.
Trade receivables, net Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Allergan Inc. trade receivables, net decreased from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Allergan Inc. inventories decreased from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014.